Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07813390) titled 'Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangdong Second Provincial General Hospital
Condition:
Acute Myeloid Leukemia (AML)
Intervention:
Drug: Lisaftoclax (APG-2575)
Drug: homoharringtonine
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2026
Target Sample Size: 73
Countries of Recruitment:
China
To know more, visit https:...